Clinical trial NCT05464784: MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Official title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MN-001 in Patients Diagnosed With Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Diabetes Mellitus, Type 2
Hypertriglyceridemia
Non-Alcoholic Fatty Liver Disease
Lead sponsor: MediciNova
Sponsor class: INDUSTRY
First posted: 2022-07-19
Enrollment: 40
Sex: ALL
Minimum age (years): 21
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The design of the Phase 2 clinical trial includes the following elements:

* Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs. placebo in approximately 40 patients in the U.S.
* Patients will be randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks.
* The co-primary endpoints are (1) change from baseline in liver fat content measured by controlled attenuation parameter (CAP) score at Week 24, and (2) change from baseline in fasting serum triglycerides at Week 24. FibroScan® is a non-invasive, quantitative, and accurate measure of liver fat content commonly used in early phase trials to measure treatment response.
* Secondary endpoints include safety and tolerability and changes in lipid profile (HDL-C, LDL-C, and total cholesterol).


Eligibility criteria: Inclusion Criteria:

* FibroScan® CAP score ≥ 248 dB/m within 8 weeks of randomization.
* Diagnosis or history of Type 2 Diabetes mellitus with hemoglobin A1c (HbA1c) \>6.5 and ≤10% at Screening.
* Fasting serum triglycerides (TG) at Screening \>150 mg/dL
* On a stable dose of oral antidiabetic therapy for a minimum of 3 months prior to Screening.

Exclusion Criteria:

* Other causes of chronic liver disease (autoimmune, primary biliary cholangitis, HBV, HCV, Wilson's, α-1-antitrypsin deficiency, hemochromatosis, biopsy-proven cirrhosis, hepatocellular carcinoma);
* Documented history of advanced liver fibrosis
* Evidence of cirrhosis, hepatic decompensation, portal hypertension including splenomegaly, ascites, encephalopathy and/or esophageal varices;
* Diagnosis or history of Diabetes mellitus type 1;
* Weight change \>5% within last 3 months of Screening visit;
* Active gastrointestinal disease or history of gastric bypass surgery which could interfere with the absorption of oral medication;
* History of clinically significant acute cardiac event within 6 months of Screening;

Primary outcomes:
measure: Mean change in controlled attenuation parameter (CAP) score by sound-based elastography at Week 24
timeFrame: Week 24
measure: Mean change from baseline in fasting serum triglyceride levels at Week 24
timeFrame: Week 24
Secondary outcomes:
measure: Safety and tolerability of MN-001
timeFrame: Baseline to Week 24
measure: Mean change from baseline in lipids
timeFrame: Baseline to Week 24
Other outcomes:
Locations:
city: Las Vegas
country: United States
facility: Jubilee Clinical Research, Inc.
state: Nevada
city: Edinburg
country: United States
facility: Pinnacle Clinical Research at South Texas Research Institute
state: Texas
Study officials:
References: